BRD2 and infection: Despite the variation in prevalence rates, we found for all regions a similar pattern of relative residual risk, as shown in Figure 4 for four NAT-nonreactive infection stages, i.e., the early pre-NAT WP (stage a), the second post -NAT WP (stage e), NAT-nonreactive OBI (stage h) and HBsAg-positive, HBV-DNA-negative donations (stage f), the latter to estimate the relative risk for a theoretical scenario in which these donations would be transfused.